Cui Yi, Wei Hongyun, Lu Fanggen, Liu Xiaowei, Liu Deliang, Gu Li, Ouyang Chunhui
Department of Gastroenterology, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province, China.
PLoS One. 2016 Feb 3;11(2):e0148241. doi: 10.1371/journal.pone.0148241. eCollection 2016.
To analyze the changes of different Lactobacillus species in ulcerative colitis patients and to further assess the therapeutic effects of selected Lactobacillus strains on dextran sulfate sodium (DSS)-induced experimental colitis in BALB/c mice.
Forty-five active ulcerative colitis (UC) patients and 45 population-based healthy controls were enrolled. Polymerase chain reaction (PCR) amplification and real-time PCR were performed for qualitative and quantitative analyses, respectively, of the Lactobacillus species in UC patients. Three Lactobacillus strains from three species were selected to assess the therapeutic effects on experimental colitis. Sixty 8-week-old BALB/c mice were divided into six groups. The five groups that had received DSS were administered normal saline, mesalazine, L. fermentum CCTCC M206110 strain, L. crispatus CCTCC M206119 strain, or L. plantarum NCIMB8826 strain. We assessed the severity of colitis based on disease activity index (DAI), body weight loss, colon length, and histologic damage.
The detection rate of four of the 11 Lactobacillus species decreased significantly (P < 0.05), and the detection rate of two of the 11 Lactobacillus species increased significantly (P < 0.05) in UC patients. Relative quantitative analysis revealed that eight Lactobacillus species declined significantly in UC patients (P < 0.05), while three Lactobacillus species increased significantly (P < 0.05). The CCTCC M206110 treatment group had less weight loss and colon length shortening, lower DAI scores, and lower histologic scores (P < 0.05), while the CCTCC M206119 treatment group had greater weight loss and colon length shortening, higher histologic scores, and more severe inflammatory infiltration (P < 0.05). NCIMB8826 improved weight loss and colon length shortening (P < 0.05) with no significant influence on DAI and histologic damage in the colitis model.
Administration of an L. crispatus CCTCC M206119 supplement aggravated DSS-induced colitis. L. fermentum CCTCC M206110 proved to be effective at attenuating DSS-induced colitis. The potential probiotic effect of L. plantarum NCIMB8826 on UC has yet to be assessed.
分析溃疡性结肠炎患者中不同乳酸杆菌种类的变化,并进一步评估所选乳酸杆菌菌株对葡聚糖硫酸钠(DSS)诱导的BALB/c小鼠实验性结肠炎的治疗效果。
招募45例活动性溃疡性结肠炎(UC)患者和45例基于人群的健康对照者。分别采用聚合酶链反应(PCR)扩增和实时PCR对UC患者中的乳酸杆菌种类进行定性和定量分析。从三种乳酸杆菌中选择三株菌株评估对实验性结肠炎的治疗效果。将60只8周龄的BALB/c小鼠分为六组。接受DSS处理的五组分别给予生理盐水、美沙拉嗪、发酵乳杆菌CCTCC M206110菌株、卷曲乳杆菌CCTCC M206119菌株或植物乳杆菌NCIMB8826菌株。我们根据疾病活动指数(DAI)、体重减轻、结肠长度和组织学损伤评估结肠炎的严重程度。
UC患者中11种乳酸杆菌中的4种检测率显著降低(P<0.05),11种乳酸杆菌中的2种检测率显著升高(P<0.05)。相对定量分析显示,UC患者中有8种乳酸杆菌显著下降(P<0.05),而3种乳酸杆菌显著增加(P<0.05)。CCTCC M206110治疗组体重减轻和结肠长度缩短较少,DAI评分和组织学评分较低(P<0.05),而CCTCC M206119治疗组体重减轻和结肠长度缩短较多,组织学评分较高,炎症浸润更严重(P<0.05)。NCIMB8826改善了体重减轻和结肠长度缩短(P<0.05),对结肠炎模型中的DAI和组织学损伤无显著影响。
补充卷曲乳杆菌CCTCC M206119加重了DSS诱导的结肠炎。发酵乳杆菌CCTCC M206110被证明可有效减轻DSS诱导的结肠炎。植物乳杆菌NCIMB8826对UC的潜在益生菌作用尚未评估。